Benefit-to-harm ratio for CDK4/6 inhibitors in the adjuvant setting: too many unanswered questions.
Both trials were remarkably unimpressive. How the authors can recommend these medicines for breast cancer when their benefit in breast cancer patients is unestablished with a straight face is stultifying.
Both trials were remarkably unimpressive. How the authors can recommend these medicines for breast cancer when their benefit in breast cancer patients is unestablished with a straight face is stultifying.